USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BOSTON BIOTECHNOLOGY CORPORATION
Address:
BOSTON BIOTECHNOLOGY CORPORATION
64 GROVE STREET
WATERTOWN, MA 02472
Phone:
(617) 658-7701
URL:
N/A
EIN:
42766443
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $871,141.00 10
SBIR Phase II $1,877,831.00 3

Award List:

AS A FUNCTION OF ETHYLENE OXIDE STERILIZATION AND STORAGE TIME.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
James b. hughes , PRINCIPAL INVESTIGATOR
Abstract:
As a function of ethylene oxide sterilization and storage time.primary biliary cirrhosis (pbc) is a degenerative liver disease of unknown etiology which frequently results in death within 5 to 10 years of the onset of symptoms. laboratory diagnosis of pbc is currently based upon histological… More

THE LONG-TERM OBJECTIVE OF THIS PROJECT IS THE DEVELOPMENT OF IMPROVED NONISOTOPIC HOMOGENEOUS IMMUNOASSAYS.

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Terence tao , PRINCIPAL INVESTIGATOR
Abstract:
The long-term objective of this project is the development of improved nonisotopic homogeneous immunoassays. initially, a method will be developed whereby sulfhydrl groups will be transferred from an antigen to an antibody selectively near the latter's antigen binding site. variousfluorescence or… More

ASBESTOS TOXICITY AND CARCINOGENICITY

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
The long range objective of this research is to reduce the toxicity and carcinogenicity of asbestos by desferroxamine treatment, which neutralizes the catalytic activity of the asbestos-contained iron. in phase i of this project the possibility that desferroxamine treatment can reduce… More

SUPERACTIVE B-GALACTOSIDASE FOR ENZYME IMMUNOASSAY

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
In diagnostic enzyme immunoassays (eia's), enzymes are conjugated with either antigen or antibody to amplify the presence of antigen-antibody complexes. currently, beta-galactosidase, horseradish peroxidase, and alkaline phosphatase are the three most widely used enzymes in these enzymes each have… More

CATALYTIC ANTIBODIES FOR THE TREATMENT OF AIDS

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$99,911.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

IMMUNOTHERAPY OF ALZHEIMERS DISEASE

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$99,489.00
Agency:
HHS
Principal Investigator:
Raso, Victor A
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Victor A. Raso
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$378,083.00
Agency:
HHS
Principal Investigator:
Victor A. Raso
Abstract:
N/a

EPITOPE-SPECIFIC ANTIBODIES FOR ALZHEIMER'S DISEASE

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Recent attempts at treating Alzheimer's patients with a beta-amyloid vaccine have resulted in an adverse brain inflammation response for a significant number in the trial group. The full-length 42 amino-acid beta-amyloid peptide was used as a vaccine in that… More

HTS for Protein Splicing Inhibitors as TB Drugs

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$297,643.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): One-third of the world' s population (2 billion people) are infected with Mycobacterium tuberculosis and 5-10% of these suffer active tuberculosis, leading to nearly 3 million deaths annually. An alarmingly growing number of patients in developed country are… More

EPITOPE-SPECIFIC ANTIBODIES FOR ALZHEIMER'S DISEASE

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$749,874.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Recent attempts at treating Alzheimer's patients with a beta-amyloid vaccine have resulted in an adverse brain inflammation response for a significant number in the trial group. The full-length 42 amino-acid beta-amyloid peptide was used as a vaccine in that… More

GHRELIN VACCINES FOR CONTROLLING OBESITY

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$74,098.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Obesity has reached epidemic proportions in the United States and adversely affects the health of both adults and children. While dieting and exercise have had little effect on the overall problem, dramatic long-term weight loss has been achieved by gastric… More

GHRELIN VACCINES FOR CONTROLLING OBESITY

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$749,874.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Obesity has reached epidemic proportions in the United States and adversely affects the health of both adults and children. While dieting and exercise have had little effect on the overall problem, dramatic long-term weight loss has been achieved by gastric… More